Introduction The new user cohort design is widely used to assess the effects of a new drug,
such as dabigatran, but inherently excludes some users due to prior use of the comparator …

Purpose: Concerns of drug–drug interactions (DDIs) between anti-seizure medications
(ASMs) and non-vitamin K oral anticoagulants (NOACs) have emerged in recent case …

Background Patient self-management (PSM) of vitamin K antagonists (VKA) seems a very
promising model of care for oral anticoagulation in terms of efficacy and safety. In …

Use of non-vitamin K antagonist oral anticoagulants (NOACs), including dabigatran
etexilate, rivaroxaban, apixaban, edoxaban or betrixaban provides a safe and convenient …

Antithrombotic agents are widely used on the globe for prevention of thrombotic events such
as atherothrombotic events and thromboembolic stroke in atrial fibrillation or for prevention …

Objective: We aimed to compare non-vitamin K oral anticoagulants (NOACs) with a
traditional antithrombotic such as vitamin K antagonist (VKA) and antiplatelet agents in …

Background The development of novel oral anticoagulants (NOACs) has changed the
landscape of non-valvular atrial fibrillation (NVAF) management. In this study, the …

Nonvalvular atrial fibrillation (NVAF) and carotid stenosis are important risk factors for stroke.
Carotid angioplasty and stent placement (CAS) is recommended for patients with …

Background/purpose Atrial fibrillation (AF) patients with a history of ischemic stroke or
transient ischemic attack (TIA) carry excessive risk of recurrent stroke. Real-world data for …

Introduction Rivaroxaban reduces the risk of thromboembolism in atrial fibrillation (AF)
patients, who often also receive antiarrhythmic drugs (AADs) to maintain sinus rhythm …